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Abstract
Background: A high prevalence of impaired glucose tolerance and unknown type 2-diabetes in
patients with coronary heart disease and no previous diagnosis of diabetes have been reported. The
aims of the present study were to investigate the prevalence of abnormal glucose regulation (AGR)
3 months after an acute ST-elevation myocardial infarction (STEMI) in patients without known
glucometabolic disturbance, to evaluate the reliability of a 75-g oral glucose tolerance test (OGTT)
performed very early after an acute STEMI to predict the presence of AGR at 3 months, and to
study other potential predictors measured in-hospital for AGR at 3 months.
Methods: This was an observational cohort study prospectively enrolling 224 STEMI patients
treated with primary PCI. An OGTT was performed very early after an acute STEMI and was
repeated in 200 patients after 3 months. We summarised the exact agreement observed, and
assessed the observed reproducibility of the OGTTs performed in-hospital and at follow up. The
patients were classified into glucometabolic categories defined according to the World Health
Organisation criteria. AGR was defined as the sum of impaired fasting glucose, impaired glucose
tolerance and type 2-diabetes.
Results: The prevalence of AGR at three months was 24.9% (95% CI 19.1, 31.4%), reduced from
46.9% (95% CI 40.2, 53.6) when measured in-hospital. Only, 108 of 201 (54%) patients remained in
the same glucometabolic category after a repeated OGTT. High levels of HbA1c and admission
plasma glucose in-hospital significantly predicted AGR at 3 months (p < 0.001, p = 0.040,
respectively), and fasting plasma glucose was predictive when patients with large myocardial
infarction were excluded (p < 0.001).
Conclusion:  The prevalence of AGR in STEMI patients was lower than expected. HbA1c,
admission plasma glucose and fasting plasma glucose measured in-hospital seem to be useful as early
markers of longstanding glucometabolic disturbance. An OGTT performed very early after a STEMI
did not provide reliable information on long-term glucometabolic state and should probably not be
recommended.
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Background
Several prospective studies have reported a high preva-
lence of impaired glucose tolerance (IGT) and unknown
type 2-diabetes (DM) in patients with coronary heart dis-
ease and no previous diagnosis of DM [1-4] although data
on patients with acute ST-elevation myocardial infarction
are scarce. IGT and DM have been shown to be strong risk
factors for future cardiovascular events after acute myocar-
dial infarction [5]. Recent European guidelines on DM,
prediabetes, and cardiovascular disease recommend that
patients without known diabetes, but with established
cardiovascular disease should be investigated with an oral
glucose tolerance test (OGTT) [6]. However a scientific
statement from the American Heart Association Diabetes
Committee of the Council on Nutrition, Physical Activity,
and Metabolism do not encourage routine use of such
screening [7]. In the European guidelines there is no con-
sensus about the timing of an OGTT performed after an
acute myocardial infarction [6]. Early testing may be con-
founded by stress reactions accompanying an acute myo-
cardial infarction, but could be important in order to
identify patients with cardiovascular events in the first
weeks after an acute myocardial infarction [8]. The Glu-
cose tolerance in Acute Myocardial Infarction (GAMI)
study indicated that an OGTT performed early (day 4–5)
after an acute myocardial infarction [1] provided reliable
information on long-term glucometabolic state [9].
Routine use of OGTT, as stated by the European guide-
lines, in the follow-up of patients with myocardial infarc-
tion has so far not been implemented in Norway. Rapid
transfer of stable patients after primary PCI from tertiary
centers to community hospitals makes it difficult to
implement the new guidelines into daily-life practice. This
study was undertaken to investigate the prevalence of
unknown DM, IGT and impaired fasting glucose (IFG) in
patients with STEMI during stable conditions after 3
months of follow-up and to evaluate the reliability of per-
forming an OGTT-based glucometabolic classification in-
hospital in order to predict glucometabolic disturbance
defined by a repeated OGTT at 3 months. The study had a
practical approach: Performing a very early OGTT at the
PCI center in stable patients, before transfer (usually
within 24 hours) back to community hospitals, in order
to establish screening for unknown DM and IGT in STEMI
patients in our community. Finally, in an explanatory
strategy, to study various biomarkers and risk factors iden-
tified during the initial hospitalisation as possible predic-
tors of DM and IGT defined at 3 months.
Methods
Study population
The study was designed as an observational cohort study
prospectively including STEMI patients treated with pri-
mary PCI admitted to the coronary care unit at Ullevål
University Hospital, Oslo, Norway, between November
2005 and May 2007. The OGTT was performed after over-
night fasting, before transfer from the coronary care unit
back to the referring hospitals. At Ullevål University Hos-
pital, stable patients are regularly returned within 24-
hours after treatment. At enrolment, patients were clini-
cally stable, without persistent glyseroltrinitrat infusion,
chest pain, nausea or symptoms of heart failure. Patients
with known DM, serum creatinine concentration ≥ 200
umol/L, and age > 85 years were excluded. The OGTT was
not performed in patients with persistent hyperglycaemia
in order to avoid further glucose overloading.
The Regional ethics committee approved the study and all
patients provided written informed consent. STEMI was
defined as ST-segment elevation of > 2 mm in two or more
contiguous chest leads or > 1 mm in two or more limb
leads or new left bundle-branch block, together with typi-
cal symptoms (chest pain or discomfort > 20 min).
Laboratory methods
Admission plasma glucose concentration was analysed
from a blood sample taken in the catheterisation labora-
tory as soon as possible after PCI. After overnight fasting,
blood samples for routine analysis by use of conventional
methods including plasma glucose, were drawn. A stand-
ardised OGTT (2 h) with 75 g of glucose dissolved in 200
mL water was performed [10]. The median time from bal-
loon to OGTT was 16 hr and 35 min. The OGTT was
repeated after three months.
Serum-cTroponin T was measured by electrochemilumi-
nescence technology for quantitative measurement (3rd
generation cTroponinT, Elecsys 2010, Roche, Mannheim,
Germany). The lower detection limit of the assay is 0.01
ug/l with a recommended diagnostic threshold of 0.03
ug/l. The inter-assay coefficient of variation was 7%.
Urinary albumin excretion was assessed in a morning spot
urine sample and expressed as albumin/creatinine ratio.
Microalbuminuria was defined as 30–300 mg albumin
secreted per 24 hours [11].
Clinical follow-up
At 3 months, the patients underwent an OGTT, clinical
examination, and answered a questionnaire about life-
style changes after discharge from hospital, including
weight, smoking habits, and physical activity. Physical
activity was reported as 30 min of activity, 0–1 days/week,
2–3 days/week, or > 3 days/week.
Single Photon Emission Computed Tomography imaging
Left ventricular ejection fraction, end-diastolic and end-
systolic volume and infarct size expressed as percent of left
ventricular mass, were assessed at rest after 3 months byCardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
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Single Photon Emission Computed Tomography imaging
with technetium 99 m-tetrofosmin [12].
Classification of glucometabolic state
The different glucometabolic categories were defined
according to the World Organisation criteria [13]. Classi-
fication of glucometabolic state was primarily based on
the result of an OGTT and the patients were divided into
one of the following four categories, (glucose levels given
in mmol/l):
Normal Glucose Regulation (NGR) = OGTT (0 min) < 6.1
and OGTT (2 h) < 7.8
Impaired Fasting Glucose (IFG) = OGTT (0 min) ≥ 6.1 <
7.0 and OGTT (2 h) < 7.8
Impaired Glucose Tolerance (IGT) = OGTT (0 min) < 7.0
and OGTT (2 h) ≥ 7.8 < 11.1
Type 2-diabetes (DM) = OGTT (0 min) ≥ 7.0 and/or OGTT
(2 h) ≥ 11.1
Because of limited number in each category, the patients
were also divided into:
Abnormal Glucose Regulation (AGR) = IFG+IGT+DM or
NGR.
The patients were also categorised based on the results of
fasting plasma glucose (FPG) only:
Normal Glucose Regulation (NGR) = FPG < 6.1
Impaired Fasting Glucose (IFG) = FPG ≥ 6.1 < 7.0
Type 2-diabetes (DM) = FPG ≥ 7.0
Statistics
In the prevalence study an apriori power analysis was per-
formed. With a hypothesised prevalence of AGR of 60%
[1-3] with a precision of 5% and a chosen probability of
90% a sample size of 222 patients was needed to deter-
mine the prevalence of unknown AGR. Furthermore, a
post hoc power analysis was done for potential in-hospi-
tal predictors for the outcome AGR at 3 months showing
that 116 patients were required considering a type 1-error
of 5%, a power of 80%, a prevalence of AGR in patients
with low HbA1c of 17%, and an OR (crude) = 4.15 for the
association HbA1c on AGR. Similar analyses were also
performed with the associations of fasting plasma glucose
and admission plasma glucose on AGR.
Values are presented as median (25, 75% quartiles) or
proportions. Mann-Whitney's test was used for comparing
groups. In order to identify possible in-hospital predictors
of AGR defined at 3 months, we hypothesised an associa-
tion between the 3 exposition variables HbA1c, fasting
plasma glucose, and admission plasma glucose and the
outcome AGR. The other variables were potential con-
founders or effect modifiers of this association. The odds
ratio (OR) and its 95% confidence interval (CI) were used
to quantify this association. We performed a stratification
analysis and dichotomised continuous exposition varia-
bles into high and low values using the cut-off point 6.1
mmol/l for fasting plasma glucose according to the litera-
ture and the 75% percentile in the present material for the
other variables. The Mantel-Haenszel method was used to
highlight potential effect modification by the Breslow-
Day test of heterogeneity and to quantify potential con-
founders [14]. Additional information is available online
(see additional file 1).
A logistic regression model, including a backward elimi-
nation procedure and finally taking in consideration the
concept of validity and precisions, performed adjustment
for multi-confounders. The STROBE guidelines were fol-
lowed [15].
Analyses were performed using Epi-info software, 2005,
version 3.3.2.
A value of p < 0.05 was considered statistically significant.
Results
Baseline and follow up characteristics
Two hundred and twenty five patients without previously
known DM or IGT were enrolled in the study. The OGTT
was well tolerated, 224 completed an in-hospital OGTT
while one patient interrupted the test because of acute
nausea. None of the patients complained of chest-pain or
underwent a new coronary angiography. No in-hospital
deaths occurred. The median time from onset of chest
pain to balloon (PCI) was 3 hr and 39 min and 16 hr and
35 min from balloon to OGTT. The OGTT was repeated in
200 patients after 3 months. The reasons for not repeating
the test were: death (n = 1), fasting plasma glucose > 7.0
mmol/L (n = 1) and unwillingness (n = 22). Table 1 sum-
marises the baseline characteristics of the study popula-
tion. Notably, the majority of the patients presented with
their first myocardial infarction, 62% had single vessel
disease and 92% of the patients were in Killip class 1 (data
not shown). Single photon emission computed tomogra-
phy imaging at 3 months showed that 85% of the patients
had an left ventricular ejection fraction > 50%.
At 3 months 25% of the patients had stopped smoking,
41% had increased the number of days per week of phys-
ical activity, 36% had lost weight and 30% had gained
weight. The proportion of AGR in patients who had lostCardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
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weight and in patients who had gained weight was 28%
and 25%, respectively (data not shown).
Prevalence of AGR
The median plasma glucose concentration at admission
was 6.9 mmol/L ((25, 75% percentiles) 6.0, 7.8), the
median fasting plasma glucose was 5.3 mmol/L (4.9, 5.9)
and the median HbA1c value was 5.5% (5.3, 5.8) (n =
207). Figure 1 shows the prevalence of NGR, IFG, IGT and
DM in-hospital and at 3 months, based on a glucometa-
bolic classification by OGTT and alternatively, by fasting
plasma glucose alone. Based on the given categories we
defined, abnormal glucose regulation (AGR) as the sum of
IFG, IGT and DM, in spite of different risk profiles
between IFG, IGT and DM. The prevalence of AGR after an
OGTT- based classification was 46.9% (95% CI 40.4,
53.9) (n = 224) in-hospital and 24.9% (19.1, 31.4) (n =
201) at 3 months, respectively.
Table 2 compares the results of an OGTT- based glucomet-
abolic classification of the patients in-hospital and at 3
months. Fifty-four % of the patients remained in the same
glucometabolic category after a repeated OGTT. Only 5
out of 22 patients defined as diabetic in-hospital
remained in the diabetic category after 3 months.
Predictors of AGR
In Table 3, patient characteristics assessed at hospitalisa-
tion are compared between the NGR group and the AGR
group, as defined by an OGTT three months later. Patients
with AGR were older, there were significantly more
women, and they had significantly higher levels of
HbA1c, admission plasma glucose, and fasting plasma
glucose.
In univariate analyses HbA1c, admission plasma glucose
and fasting plasma glucose significantly predicted the
presence of AGR at 3 months (p < 0.001, p = 0.006 and p
= 0.011, respectively) (Table 4). HbA1c (p < 0.001) and
admission plasma glucose (p = 0.040), analysed sepa-
rately, remained significantly predictive after adjustment
for confounders (Table 4). When analysing on fasting
plasma glucose concentration as an independent biomar-
ker, serum-cTroponinT modified the effect of fasting
plasma glucose on AGR, thus the results were stratified
into two subgroups, and as shown in Table 4, fasting
plasma glucose was independently predicting AGR at 3
months only in patients with serum-cTroponin T below
the highest quartile (< 8.80 ug/l), with an adjusted OR
5.50 (95% CI 2.00, 15.10).
Discussion
Prevalence of AGR
The main findings in the present study were that only 25%
of the patients were classified by OGTT as having AGR in
a clinically steady situation 3 months after an acute STEMI
and only about 5% had previously unknown DM. About
50% of the patients with STEMI were classified as having
undetected AGR based on an OGTT classification in-hos-
pital, but only half of these patients remained in the AGR
group after a repeated OGTT 3 months later. Using fasting
plasma glucose classification only, about 50% of the
patients with AGR would have been misclassified, both
in-hospital and after 3 months. To disclose the actual glu-
cometabolic state in these patients it seems necessary to
perform an OGTT. The latter result is in line with a previ-
ous study, showing that two-thirds of the patients with
undiagnosed diabetes would have been missed using fast-
ing plasma glucose classification alone [2].
In the present study the OGTT was performed very early
after a PCI treated STEMI and an initially higher preva-
lence of AGR could be expected as an acute STEMI is
accompanied by a substantial release of stress hormones.
However, we found a somewhat lower prevalence of AGR
than reported in previous studies, both in-hospital and at
3 months. Three prospective studies on mixed popula-
tions of patients with acute and stable coronary artery dis-
Table 1: Baseline characteristics of the total population (n = 
224)
Patients
Age (years) 58 (51, 67)
Male 185 (82.6%)
Previous disorder:
Myocardial infarction 16 (7.1%)
Angina pectoris 7 (3.1%)
Hypertension (treated) 58 (25.9%)
Hyperlipidaemia (treated) 20 (8.9%)
Status at baseline
Current smoker 109 (48.7%)
BMI (kg/m2) 26 (24.4, 28.7)
Waist circumference (cm) 100 (94, 107)
Stent in culprit lesion 215 (96.0%)
Gp IIb/IIIa antagonist treated 79 (35.3%)
Single -coronary vessel disease 139 (62.1%)
Double-coronary vessel disease 64 (28.6%)
Triple-coronary vessel disease 21 (9.4%)
Time from symptoms to balloon (min) 219 (140, 378)
Time from PCI to OGTT (min) 995 (689, 1277)
Medication at discharge from CCU
Aspirin 224 (100%)
Clopidogrel 222 (99.1%)
β-blockers 181 (80.8%)
Lipid lowering agents 221 (98.7%)
Angiotensin converting enzyme-inhibitors 36 (16.1%)
Angiotensin II-receptor blockers 18 (8.0%)
LVEFa 64 (56, 70)
Data are presented as median with inter-quartile range or 
proportions.
BMI: body mass index, LVEF: left ventricular ejection fraction. aLVEF 
diagnosed 3 months after discharge.Cardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
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ease have shown that about 60% of the patients had
undiagnosed AGR [1-3]. A repeated OGTT was performed
only in one of these studies showing that 66% of the
patients had AGR before hospital discharge [1] and the
prevalence was reported to be similar after 3 and 12
months [9]. In the present study the prevalence of AGR at
3 months was much lower, which the selected population
of STEMI patients may partly explain. The patients were
mainly Caucasians, relatively young, included a low
number of women, a high proportion of first acute myo-
cardial infarction, and a preponderance of single vessel
disease. Additionally, patients with persistent hypergly-
caemia were excluded. It is possible that the prevalence of
AGR after 3 months would have been higher if these
patients had been included in the 3 months follow-up.
The prevalence of AGR was reduced by about 50% after 3
months indicating poor reliability of the early classifica-
Glucometabolic classification of 201 STEMI patients based on the results of an OGTT or fasting plasma glucose only, in-hospital  and at 3 months Figure 1
Glucometabolic classification of 201 STEMI patients based on the results of an OGTT or fasting plasma glu-
cose only, in-hospital and at 3 months. FPG: fasting plasma glucose, IFG: impaired fasting glucose, IGT: impaired glucose 
tolerance, NGR: normal glucose regulation, OGTT: oral glucose tolerance test, DM: type 2-diabetes.
Table 2: Glucometabolic classification by OGTT in patients with ST-elevation infarction in-hospital (OGTT1, row), and at 3 months 
(OGTT2, column)
NGR (OGTT2) IFG (OGTT2) IGT (OGTT2) DM (OGTT2) Total (OGTT1)
NGR (OGTT1) 91 6 11 1 109
IFG (OGTT1) 8 1 1 0 10
IGT (OGTT1) 41 4 11 4 60
DM (OGTT1) 11 0 6 5 22
Total (OGTT2) 151 11 29 10 201
Data are number of patients.
Observed concordance: 53.7%
One patient was categorized based on the results of fasting plasma glucose only, because of persistent hyperglycaemia.Cardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
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tion. The measured in-hospital prevalence of AGR reflects
not only long-standing glucometabolic disturbance, but
also an acute stress epiphenomenon as discussed.
OGTT in patients with STEMI
Patients with acute myocardial infarction and diabetes
have a higher short and long-term mortality rate than
non-diabetic patients [16]. The 2-hour blood glucose has
been shown to be superior to fasting blood glucose to pre-
dict the risk of future cardiovascular disease and death
from all causes in individuals with hyperglycaemia [17].
The present study revealed that a very early OGTT in
STEMI-patients was well tolerated, except in one patient.
None of the patients died in-hospital, reflecting the inten-
tion to exclude unstable patients.
To examine the reproducibility of an OGTT, two inde-
pendent tests should be performed within a short period
of time in stable patients without persistent acute ill-
ness[10]. Even under these circumstances previous studies
have suggested poor reproducibility of an OGTT [18]. In
the present study we compared the OGTT performed after
initial stabilisation of acute illness, and stable disease,
thus we did not test the reproducibility of the OGTT, but
evaluated the reliability of an early glucometabolic classi-
fication by OGTT by repeating the test after 3 months.
Generally, the variation in the repeated OGTT results has
to a great extent been explained by the random variation
of plasma glucose concentration [19]. In our study the
variation in the OGTT results after 3 months of follow up
to a great extent may have been influenced by the different
test situation mentioned. This is in line with another
Table 3: Clinical and laboratory characteristics of patients in-hospital according to glucometabolic category defined by OGTT at 3 
months
NGR (n = 151) AGR (n = 50) P
Age (years) 57 (51, 65) 61 (52, 72) 0.037
Male 129 (85.4%) 36 (72.0%) 0.032
Current smoker 67 (44.4%) 24 (48.0%) 0.656
Treated hypertension 38 (25.2%) 17 (34.0%) 0.226
BMI (kg/m2) 26.2 (24.3, 28.7) 26.1 (24.6, 28.7) 0.741
Cholesterol (mmol/l) 5.1 (4.4, 5.7) 5.1 (4.4, 5.7) 0.839
Triglycerides (mmol/l) 1.27(0.89, 1.79) 1.25 (0.96, 1.83) 0.623
HDL-cholesterol (mmol/l) 1.19 (0.97, 1.43) 1.12 (1.00, 1.35) 0.659
Serum uric acid (mmol/l) 334 (289, 382) 347 (282, 409) 0.288
Microalbuminuria 26 (18.2%) 10 (22.2%) 0.549
scTnT (ug/l) 4.85 (2.45, 8.31) 4.97 (2.38, 10.25) 0.469
HbA1c (%) 5.5 (5.3, 5.7) 5.8 (5.5, 6.0) < 0.001
Admission plasma glucose (mmol/l) 6.6 (5.8, 7.5) 7.4 (6.6, 8.7) <0.001
FPG (mmol/l) 5.2 (4.9, 5.7) 5.6 (5.1, 6.3) 0.003
Data are presented as median with inter-quartile range or proportions.
AGR: abnormal glucose regulation, BMI: body-mass index, FPG: fasting plasma glucose, NGR: normal glucose regulation, scTnT: serum-cTroponinT.
Table 4: Logistic regression analysis of HbA1c, admission plasma glucose and fasting plasma glucose as independent predictors in-
hospital for AGR defined by an OGTT at 3 months
AGR AGR AGR
scTnT > 8.80 ug/l
(n = 51)
AGR
scTnT < 8.80 ug/l
(n = 150)
OR (crude)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P
HbA1ca
> 5.7%
4.15
(2.03, 8.48)
<0.001 3.76
(1.82, 7.79)
<0.001
Admission plasma glucoseb
> 7.7 mmol/l
2.59
(1.31, 5.12)
0.006 2.12
(1.03, 4.33)
0.040
FPG c
≥ 6.1 mmol/L
2.62
(1.25, 5.50)
0.011 0.69
(0.15, 3.14)
0.636 5.50
(2.00, 15.10)
<0.001
AGR: abnormal glucose regulation, FPG: fasting plasma glucose, scTnT: serum-cTroponinT.
aAdjusted for gender and age.
bAdjusted for age.
cscTnT > 8.80 ug/l (highest quartile) was an effect modifier on the association FPG on AGR, thus data are presented in 2 subgroups, both adjusted 
for age, uric acid and gender.Cardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
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study showing that acute myocardial infarction induces
hyperglycaemia and give rice to insulin resistance [20].
These investigators demonstrated that blood glucose lev-
els and HOMA-IR decreased significantly during hospital
stay with no further decrease between discharge (day 4–5)
and 3 months of follow up reflecting that acute illness
influence the very early rise and fall in glucose levels in-
hospital [20].
Only 54% of the patients in our study were classified into
the same glucometabolic state on both occasions which is
in accordance with results from other studies performing
repeated OGTTs [20,21]. The intra-individual tracking of
oral glucose tolerance in our study was poor, but compa-
rable to what was found in the GAMI study (49 and 54%,
respectively) [20]. In the present study, 11 out of 22
patients classified as having diabetes in-hospital con-
verted to NGR at 3 months. These results underline the
World Health Organisation recommendation for a
repeated OGTT under stable conditions to confirm or
exclude an abnormality of glucose regulation in asympto-
matic individuals [10]. Nevertheless, individuals with one
abnormal OGTT have been shown to have a higher cardi-
ovascular risk profile compared to individuals who had
two normal OGTTs [18] and a single positive OGTT in
patients with acute myocardial infarction seems to iden-
tify patients at higher risk of future cardiovascular event
[5]. The present study do not address whether an early
OGTT after a myocardial infarction can identify patients
with worse prognosis.
Predictors of AGR
In order to identify patients with AGR after 3 months
without performing an in-hospital OGTT, analysis of risk
markers was undertaken. We could not demonstrate any
differences in baseline values of conventional cardiovas-
cular disease risk factors between the AGR and NGR
groups, classified after 3 months. However, a high HbA1c
value and a high admission plasma glucose value in-hos-
pital were independently predicting AGR at 3 months
with an adjusted OR of 3.76 and 2.12, respectively. Fur-
thermore, a high fasting plasma glucose value in-hospital,
strongly predicted AGR at 3 months (adjusted OR 5.50),
when patients with large myocardial infarction were
excluded indicating that an acute stress reaction may
dominate in patients with a large acute myocardial infarc-
tion.
This is in accordance with other studies showing HbA1c
values at admission and fasting plasma glucose at dis-
charge from hospital (day 4 after acute myocardial infarc-
tion) to be independent predictors of AGR at 3 months
[1].
Clinical implication
The European guidelines recommend that patients with-
out known diabetes, but with established cardiovascular
disease should be investigated with an OGTT [6]. In order
to try to implement the new guidelines in our region we
performed an OGTT before transfer to referring hospitals.
The present results demonstrate that it is safe to perform a
very early OGTT in stable patients with acute STEMI, but
a very early classification did not provide reliable informa-
tion on long-term glucometabolic state, and the present
results do not encourage routine use of an OGTT at this
early time point in acute STEMI patients However, a sub-
stantial proportion of the patients had undetected AGR
after 3 months and it is important to diagnose these
patients and offer them a close follow- up on lifestyle
interventions and optimal medical treatment in order to
reduce events in this high-risk population.
Limitations
Unstable patients and patients with persistent hypergly-
caemia in-hospital were excluded from the study to avoid
further glucose loading, possibly making a selection bias
towards more glucometabolically normal patients. This
may have contributed to the somewhat unexpected low
prevalence of undetected AGR in STEMI patients.
Conclusion
The prevalence of AGR in a STEMI-population was lower
than previously reported in patients with acute myocar-
dial infarction. The prevalence was relatively high when
measured in-hospital by a very early OGTT, but half of
these patients were categorised as having normal glucose
regulation when re-tested at 3 months. Based on these
results an OGTT should probably not be recommended
very early after an acute STEMI whereas an OGTT should
be performed during follow-up in order to identify
patients with persistent glucometabolic disturbances.
High levels of HbA1c, admission plasma glucose and fast-
ing plasma glucose (except in patients with large myocar-
dial infarction) measured in-hospital predicted an
increased risk of AGR defined at 3 months, indicating that
these biomarkers can be used as early markers of a long
standing glucometabolic disturbance in patients with
acute myocardial infarction.
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